An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia

Prospective Study Evaluating the Quality of Life in Dialysis Patients With End Stage Renal Disease

This multicenter, prospective, observational study will evaluate the quality of life and the factors that influence the quality of life of epoetin beta [Neorecormon] in patients with renal chronic anemia, who are on dialysis. For each eligible patient data will be collected for 6 months. Target sample size is 5000-7000 patients.

Inclusion Criteria:

• Adult patients >/=18 years of age
• Dialysis patients with chronic renal anemia
• Written informed consent

Exclusion Criteria:

• Red blood cell transfusion in the previous 2 months
• Severe neuropsychological disorder
• Diabetic patients with serious complications

This trial is being conducted in Morocco.